Juno Therapeutics Inc.'s origins in three of the country's top oncology centers apparently has done plenty to help financing options for the Seattle-based firm, which added $134 million in series B cash to boost its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline. In less than 12 months, the Seattle-based company has raised more than $300 million.